29 January 2021 (Friday) - A.S.H. Update

The nice people at the American Society of Hematology sent  a little update on MDS and myeloproliferative neoplasms today. Possibly not directly applicable to my daily round, but background information is always useful…

Loss of STK11/LKB1 Drives Progression to Leukemia in Myeloproliferative Neoplasms Results from a CRISPR/Cas9 screening study presented at the 2020 ASH Annual Meeting suggest that STK11 could serve as a potential candidate tumor suppressor gene in patients with post-MPN acute myeloid leukemia.

Imetelstat Improves Rate of Durable Transfusion Independence in Patients With Lower-Risk MDS Treatment with imetelstat was associated with a clinically meaningful rate of transfusion independence in heavily transfused patients with lower-risk MDS, according to study results published in the Journal of Clinical Oncology.

Machine Learning Detects Prognostic Associations Between Morphologic and Genetic Changes in MDS A new artificial intelligence–based technique was able to establish correlations between genetic and morphologic biomarkers, revealing diagnostically and prognostically important relationships, according to results published in Blood.